Literature DB >> 28667552

Paying for the Tolls: The High Cost of the Innate Immune System for the Cardiac Myocyte.

Anne A Knowlton1,2,3.   

Abstract

The cardiac myocyte differs strikingly from the specialized cells of the immune system, which has two different responses to invading organisms and tissue damage. Adaptive or acquired immunity generates highly specific antibodies in response to threats and is an essential component of immunity; however, adaptive immunity can take 4-7 days to mobilize, and a more primitive response, innate immunity, fills the gap. Innate immunity is expressed in complex and in primitive life forms. Specialized receptors, Toll-like receptors (TLRs), which are widely distributed throughout different tissues recognize danger signals and rapidly respond with the release of noxious substances, such as TNFα. The problem is that many endogenous molecules have been found to act as ligands for specific TLRs, and when these molecules are released into the extracellular environment, they can cause problems by activating innate immunity and an inflammatory response. In cardiac myocytes heat shock protein (HSP)60 can activate TLR4, as can HMGB1, and this type of response can amplify the response to ischemia/reperfusion leading to increased cell and tissue injury. Activation of TLRs can potentially amplify chronic, inflammatory diseases, such as ischemic heart failure. Thus, it is important to understand the regulation of the TLRs and their downstream effects. This chapter will focus on the TLRs and cardiac myocytes.

Entities:  

Keywords:  Antibodies; Apoptosis; Cardiac myocytes; HSP60; HSP70; Heart failure; Inflammatory cytokines; Innate immunity; Necrosis; TLR2; TLR4; TNF; Toll-like receptors

Mesh:

Substances:

Year:  2017        PMID: 28667552     DOI: 10.1007/978-3-319-57613-8_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

Review 1.  Tumor necrosis factor receptor-associated factor 6 as a nuclear factor kappa B-modulating therapeutic target in cardiovascular diseases: at the heart of it all.

Authors:  Muhammad Abdullah; Jessica M Berthiaume; Monte S Willis
Journal:  Transl Res       Date:  2017-11-07       Impact factor: 7.012

Review 2.  Immune Modulation in Heart Failure: the Promise of Novel Biologics.

Authors:  Paulino Alvarez; Alexandros Briasoulis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-15

3.  SIRT1 Mediates Septic Cardiomyopathy in a Murine Model of Polymicrobial Sepsis.

Authors:  Lane M Smith; Barbara K Yoza; J Jason Hoth; Charles E McCall; Vidula Vachharajani
Journal:  Shock       Date:  2020-07       Impact factor: 3.533

Review 4.  Heat Shock Protein 60 in Cardiovascular Physiology and Diseases.

Authors:  Yaoyun Duan; Huayuan Tang; Kali Mitchell-Silbaugh; Xi Fang; Zhen Han; Kunfu Ouyang
Journal:  Front Mol Biosci       Date:  2020-04-30

5.  aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model.

Authors:  Jinmiao Chen; Qing Ma; Justin S King; Yan Sun; Bing Xu; Xiaoyu Zhang; Sylvia Zohrabian; Haipeng Guo; Wenqing Cai; Gavin Li; Ivone Bruno; John P Cooke; Chunsheng Wang; Maria Kontaridis; Da-Zhi Wang; Hongbo Luo; William T Pu; Zhiqiang Lin
Journal:  Life Sci Alliance       Date:  2019-12-16

Review 6.  Heat shock protein 60 and cardiovascular diseases: An intricate love-hate story.

Authors:  Indumathi Krishnan-Sivadoss; Iván A Mijares-Rojas; Ramiro A Villarreal-Leal; Guillermo Torre-Amione; Anne A Knowlton; C Enrique Guerrero-Beltrán
Journal:  Med Res Rev       Date:  2020-08-17       Impact factor: 12.388

7.  Downregulation of DEC1 by RNA interference attenuates ischemia/reperfusion-induced myocardial inflammation by inhibiting the TLR4/NF-κB signaling pathway.

Authors:  Weipan Xu; Kai Zhang; Yi Zhang; Shanxue Ma; Daoqun Jin
Journal:  Exp Ther Med       Date:  2020-04-30       Impact factor: 2.447

Review 8.  Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure.

Authors:  Mark F McCarty
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.